TWI482628B - 新穎之血栓溶解病患次群 - Google Patents
新穎之血栓溶解病患次群 Download PDFInfo
- Publication number
- TWI482628B TWI482628B TW097139886A TW97139886A TWI482628B TW I482628 B TWI482628 B TW I482628B TW 097139886 A TW097139886 A TW 097139886A TW 97139886 A TW97139886 A TW 97139886A TW I482628 B TWI482628 B TW I482628B
- Authority
- TW
- Taiwan
- Prior art keywords
- stroke
- cerebral artery
- patient
- bat
- patients
- Prior art date
Links
- 230000002537 thrombolytic effect Effects 0.000 title claims description 32
- 208000006011 Stroke Diseases 0.000 claims description 57
- 102000004190 Enzymes Human genes 0.000 claims description 24
- 108090000790 Enzymes Proteins 0.000 claims description 24
- 239000003146 anticoagulant agent Substances 0.000 claims description 23
- 230000010102 embolization Effects 0.000 claims description 23
- 206010061216 Infarction Diseases 0.000 claims description 20
- 230000007574 infarction Effects 0.000 claims description 20
- 210000003657 middle cerebral artery Anatomy 0.000 claims description 18
- 210000003388 posterior cerebral artery Anatomy 0.000 claims description 13
- 210000002551 anterior cerebral artery Anatomy 0.000 claims description 12
- 206010018985 Haemorrhage intracranial Diseases 0.000 claims description 10
- 208000008574 Intracranial Hemorrhages Diseases 0.000 claims description 10
- 230000010108 arterial embolization Effects 0.000 claims description 8
- 230000037396 body weight Effects 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 208000010125 myocardial infarction Diseases 0.000 claims description 5
- 208000024891 symptom Diseases 0.000 claims description 5
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 4
- 208000032851 Subarachnoid Hemorrhage Diseases 0.000 claims description 4
- 230000001154 acute effect Effects 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 201000008450 Intracranial aneurysm Diseases 0.000 claims description 3
- 210000001627 cerebral artery Anatomy 0.000 claims description 3
- 230000036244 malformation Effects 0.000 claims description 2
- 206010008092 Cerebral artery thrombosis Diseases 0.000 claims 1
- ALPWRKFXEOAUDR-GKEJWYBXSA-M sodium;[(2r)-2,3-di(octadecanoyloxy)propyl] hydrogen phosphate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)([O-])=O)OC(=O)CCCCCCCCCCCCCCCCC ALPWRKFXEOAUDR-GKEJWYBXSA-M 0.000 description 30
- 229940127126 plasminogen activator Drugs 0.000 description 24
- 102000001938 Plasminogen Activators Human genes 0.000 description 23
- 108010001014 Plasminogen Activators Proteins 0.000 description 23
- 210000001519 tissue Anatomy 0.000 description 21
- 238000002560 therapeutic procedure Methods 0.000 description 19
- 239000000902 placebo Substances 0.000 description 18
- 229940068196 placebo Drugs 0.000 description 18
- 229940088598 enzyme Drugs 0.000 description 14
- 102000009123 Fibrin Human genes 0.000 description 12
- 108010073385 Fibrin Proteins 0.000 description 12
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 12
- 229950003499 fibrin Drugs 0.000 description 12
- 230000004044 response Effects 0.000 description 12
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 10
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 10
- 230000008520 organization Effects 0.000 description 9
- 229960003318 alteplase Drugs 0.000 description 8
- 238000002591 computed tomography Methods 0.000 description 8
- 230000003902 lesion Effects 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 238000002583 angiography Methods 0.000 description 7
- 210000004204 blood vessel Anatomy 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 230000010412 perfusion Effects 0.000 description 7
- 230000002792 vascular Effects 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 6
- 241000288900 Desmodus rotundus Species 0.000 description 5
- 239000012190 activator Substances 0.000 description 5
- 230000003993 interaction Effects 0.000 description 5
- 230000000302 ischemic effect Effects 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 108010057987 Desmodus rotundus salivary plasminogen activator alpha 1 Proteins 0.000 description 4
- 208000032382 Ischaemic stroke Diseases 0.000 description 4
- 102000013566 Plasminogen Human genes 0.000 description 4
- 108010051456 Plasminogen Proteins 0.000 description 4
- 230000017531 blood circulation Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 208000005189 Embolism Diseases 0.000 description 3
- 206010057469 Vascular stenosis Diseases 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 210000005013 brain tissue Anatomy 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 238000002203 pretreatment Methods 0.000 description 3
- 210000003296 saliva Anatomy 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 208000022211 Arteriovenous Malformations Diseases 0.000 description 2
- 206010014513 Embolism arterial Diseases 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 206010029350 Neurotoxicity Diseases 0.000 description 2
- 208000031481 Pathologic Constriction Diseases 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 108010023197 Streptokinase Proteins 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 206010044221 Toxic encephalopathy Diseases 0.000 description 2
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 2
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000005744 arteriovenous malformation Effects 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 208000034158 bleeding Diseases 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 230000008499 blood brain barrier function Effects 0.000 description 2
- 210000001218 blood-brain barrier Anatomy 0.000 description 2
- 230000007012 clinical effect Effects 0.000 description 2
- 238000010968 computed tomography angiography Methods 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 229950001282 desmoteplase Drugs 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000003527 fibrinolytic agent Substances 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 231100000228 neurotoxicity Toxicity 0.000 description 2
- 230000007135 neurotoxicity Effects 0.000 description 2
- 231100000501 nonneurotoxic Toxicity 0.000 description 2
- 230000001991 pathophysiological effect Effects 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 238000012950 reanalysis Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000010410 reperfusion Effects 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 230000036262 stenosis Effects 0.000 description 2
- 208000037804 stenosis Diseases 0.000 description 2
- 229960005202 streptokinase Drugs 0.000 description 2
- 229960005356 urokinase Drugs 0.000 description 2
- 101150084750 1 gene Proteins 0.000 description 1
- 206010002329 Aneurysm Diseases 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000000483 Central Nervous System Vascular Malformations Diseases 0.000 description 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 208000004929 Facial Paralysis Diseases 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000018899 Glutamate Receptors Human genes 0.000 description 1
- 108010027915 Glutamate Receptors Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000029797 Prion Human genes 0.000 description 1
- 108091000054 Prion Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 108010039185 Tenecteplase Proteins 0.000 description 1
- 208000036826 VIIth nerve paralysis Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- VLSMHEGGTFMBBZ-UHFFFAOYSA-N alpha-Kainic acid Natural products CC(=C)C1CNC(C(O)=O)C1CC(O)=O VLSMHEGGTFMBBZ-UHFFFAOYSA-N 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000000386 athletic effect Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 201000011529 cardiovascular cancer Diseases 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000003727 cerebral blood flow Effects 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 210000004720 cerebrum Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 239000002872 contrast media Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000003073 embolic effect Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 230000004424 eye movement Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- VLSMHEGGTFMBBZ-OOZYFLPDSA-N kainic acid Chemical compound CC(=C)[C@H]1CN[C@H](C(O)=O)[C@H]1CC(O)=O VLSMHEGGTFMBBZ-OOZYFLPDSA-N 0.000 description 1
- 229950006874 kainic acid Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 210000001259 mesencephalon Anatomy 0.000 description 1
- 235000020938 metabolic status Nutrition 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000007971 neurological deficit Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 231100000189 neurotoxic Toxicity 0.000 description 1
- 230000002887 neurotoxic effect Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000033885 plasminogen activation Effects 0.000 description 1
- 210000002706 plastid Anatomy 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 238000012805 post-processing Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 210000004129 prosencephalon Anatomy 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 238000002601 radiography Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 229960002917 reteplase Drugs 0.000 description 1
- 108010051412 reteplase Proteins 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 229960000216 tenecteplase Drugs 0.000 description 1
- 229960000103 thrombolytic agent Drugs 0.000 description 1
- 229960000187 tissue plasminogen activator Drugs 0.000 description 1
- 238000003325 tomography Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 238000012285 ultrasound imaging Methods 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/49—Urokinase; Tissue plasminogen activator
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Magnetic Resonance Imaging Apparatus (AREA)
- Enzymes And Modification Thereof (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Electrotherapy Devices (AREA)
- Saccharide Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07020401A EP2050462A1 (en) | 2007-10-18 | 2007-10-18 | Improved treatment of stroke patients |
| EP07022867 | 2007-11-26 | ||
| EP08017954 | 2008-10-15 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW200927164A TW200927164A (en) | 2009-07-01 |
| TWI482628B true TWI482628B (zh) | 2015-05-01 |
Family
ID=40567844
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW097139886A TWI482628B (zh) | 2007-10-18 | 2008-10-17 | 新穎之血栓溶解病患次群 |
Country Status (28)
| Country | Link |
|---|---|
| US (2) | US20100272704A1 (enExample) |
| EP (1) | EP2211898B1 (enExample) |
| JP (2) | JP5509085B2 (enExample) |
| KR (1) | KR20100089077A (enExample) |
| CN (1) | CN101903039B (enExample) |
| AR (1) | AR068914A1 (enExample) |
| AU (1) | AU2008314048B2 (enExample) |
| BR (1) | BRPI0817785A2 (enExample) |
| CA (1) | CA2702378A1 (enExample) |
| CL (1) | CL2009000752A1 (enExample) |
| CY (1) | CY1118417T1 (enExample) |
| DK (1) | DK2211898T3 (enExample) |
| EA (1) | EA020776B1 (enExample) |
| ES (1) | ES2611155T3 (enExample) |
| HR (1) | HRP20170001T1 (enExample) |
| HU (1) | HUE032867T2 (enExample) |
| IL (1) | IL205175A0 (enExample) |
| LT (1) | LT2211898T (enExample) |
| MX (1) | MX2010004157A (enExample) |
| MY (1) | MY159200A (enExample) |
| NZ (1) | NZ584640A (enExample) |
| PL (1) | PL2211898T3 (enExample) |
| PT (1) | PT2211898T (enExample) |
| RS (1) | RS55590B1 (enExample) |
| SI (1) | SI2211898T1 (enExample) |
| TW (1) | TWI482628B (enExample) |
| WO (1) | WO2009049914A2 (enExample) |
| ZA (1) | ZA201002548B (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10153601A1 (de) | 2001-11-02 | 2003-05-22 | Paion Gmbh | DSPA zur Behandlung von Schlaganfall |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060135425A1 (en) * | 2003-05-02 | 2006-06-22 | Paion Deutschland Gmbh | Intravenous injection of plasminogen non-neurotoxic activators for treating cerebral stroke |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4766075A (en) * | 1982-07-14 | 1988-08-23 | Genentech, Inc. | Human tissue plasminogen activator |
| US5244806A (en) * | 1985-08-26 | 1993-09-14 | Eli Lilly And Company | DNA encoding novel tissue plasminogen activator derivatives having kringles 1 and 2 deleted, vectors and host cells |
| IL87276A (en) * | 1987-08-03 | 1995-07-31 | Fujisawa Pharmaceutical Co | Analog of tissue plasminogen activator comprising only the kringle 2 and protease domain dna encoding the same processes for the preparation thereof and pharmaceutical compositions containing the same |
| US5094953A (en) * | 1988-03-21 | 1992-03-10 | Genentech, Inc. | Human tissue plasminogen activator variants |
| FI100403B (fi) * | 1988-07-20 | 1997-11-28 | Schering Ag | Menetelmä glykosyloitujen tai glykosyloimattomien vampyyrilepakon sylj en plasminogeeniaktivaattoreiden valmistamiseksi |
| US5714145A (en) * | 1988-09-02 | 1998-02-03 | Genentech, Inc. | Tissue plasminogen activator having zymogenic or fibrin specific properties |
| US5676947A (en) * | 1989-02-07 | 1997-10-14 | Boehringer Manneheim Gmbh | Method for treating thromboembolic conditions using thrombolytically active proteins |
| DE3903581A1 (de) * | 1989-02-07 | 1990-08-16 | Boehringer Mannheim Gmbh | Gewebs-plasminogenaktivator-derivat |
| US6008019A (en) * | 1989-02-13 | 1999-12-28 | Schering Aktiengesellschaft | Plasminogen activator from saliva of the vampire bat |
| US5891664A (en) * | 1989-04-07 | 1999-04-06 | Cancerforskningsfondet Af 1989 | Vectors and methods for recombinant production of uPA-binding fragments of the human urokinase-type plasminogen receptor (uPAR) |
| US5326700A (en) * | 1990-11-06 | 1994-07-05 | Eli Lilly And Company | DNA sequences encoding t-PA derivatives with cleavable sites |
| DK0580685T3 (da) * | 1991-04-16 | 1996-03-04 | Boehringer Mannheim Gmbh | Farmaceutisk emballageenhed indeholdende plasminogenaktivatorer til flerfoldig bolusindgift |
| US5595736A (en) * | 1991-04-22 | 1997-01-21 | Eli Lilly And Company | Compounds and methods for treatment of thromboembolic disorders |
| RU2183214C2 (ru) * | 1992-12-04 | 2002-06-10 | Шеринг Аг | Природный и рекомбинантный ингибиторы тромбина, их получение и применение |
| US5510330A (en) * | 1994-03-25 | 1996-04-23 | Boehringer Mannheim Gmbh | Combinations of thrombolytically active proteins and non-heparin anticoagulants, and uses thereof. |
| GB9412131D0 (en) * | 1994-06-17 | 1994-08-10 | British Bio Technology | Thrombolytic composition |
| US5827832A (en) * | 1995-03-06 | 1998-10-27 | Interneuron Pharmaceuticals, Inc. | Method of protecting brain tissue from cerebral infarction subsequent to ischemia |
| US5786187A (en) * | 1995-09-21 | 1998-07-28 | The Research Foundation Of State University Of New York | Method for reducing neuronal degeneration associated with seizure |
| US5945432A (en) * | 1995-12-22 | 1999-08-31 | The University Of Vermont And State Agricultural College | Thrombolytic agents and thienopyridine derivatives in acute stroke |
| US20020081294A1 (en) * | 1996-01-23 | 2002-06-27 | Genentech, Inc. | Co-administration of a thrombolytic and an anti-CD18 antibody in stroke |
| US5731186A (en) * | 1996-02-05 | 1998-03-24 | Schering Aktiengesellschaft | Method for the production of rDSPA α1 |
| US6354999B1 (en) * | 2000-01-14 | 2002-03-12 | Florence Medical Ltd. | System and method for detecting, localizing, and characterizing occlusions and aneurysms in a vessel |
| GB0025473D0 (en) * | 2000-10-17 | 2000-11-29 | Pfizer Ltd | Pharmaceutical combinations |
| DE10153601A1 (de) * | 2001-11-02 | 2003-05-22 | Paion Gmbh | DSPA zur Behandlung von Schlaganfall |
| US20080057050A1 (en) * | 2003-05-02 | 2008-03-06 | Paion Deutschland Gmbh | Intravenous injection of plasminogen non-neurotoxic activators for treating cerebral stroke |
| KR20060015721A (ko) * | 2003-05-05 | 2006-02-20 | 파이온 도이치란트 게엠베하 | 신경보호제로서의 글루타메이트 수용체 길항제 |
| US20050085478A1 (en) * | 2003-08-22 | 2005-04-21 | Pharmacia Corporation | Compositions of a cyclooxygenase-2 selective inhibitor and a low-molecular-weight heparin for the treatment of central nervous system damage |
| WO2007025219A2 (en) * | 2005-08-25 | 2007-03-01 | Biogen Idec Ma Inc. | Nogo receptor polypeptides and polypeptide fragments and uses thereof |
-
2008
- 2008-10-17 AR ARP080104540A patent/AR068914A1/es unknown
- 2008-10-17 TW TW097139886A patent/TWI482628B/zh not_active IP Right Cessation
- 2008-10-20 KR KR1020107010609A patent/KR20100089077A/ko not_active Ceased
- 2008-10-20 PT PT88388970T patent/PT2211898T/pt unknown
- 2008-10-20 RS RS20170031A patent/RS55590B1/sr unknown
- 2008-10-20 EP EP08838897.0A patent/EP2211898B1/en active Active
- 2008-10-20 PL PL08838897T patent/PL2211898T3/pl unknown
- 2008-10-20 US US12/682,779 patent/US20100272704A1/en not_active Abandoned
- 2008-10-20 WO PCT/EP2008/008871 patent/WO2009049914A2/en not_active Ceased
- 2008-10-20 SI SI200831750A patent/SI2211898T1/sl unknown
- 2008-10-20 DK DK08838897.0T patent/DK2211898T3/en active
- 2008-10-20 CA CA2702378A patent/CA2702378A1/en not_active Abandoned
- 2008-10-20 CN CN200880112073.2A patent/CN101903039B/zh not_active Expired - Fee Related
- 2008-10-20 NZ NZ584640A patent/NZ584640A/xx not_active IP Right Cessation
- 2008-10-20 BR BRPI0817785-6A patent/BRPI0817785A2/pt not_active IP Right Cessation
- 2008-10-20 ES ES08838897.0T patent/ES2611155T3/es active Active
- 2008-10-20 MX MX2010004157A patent/MX2010004157A/es active IP Right Grant
- 2008-10-20 HR HRP20170001TT patent/HRP20170001T1/hr unknown
- 2008-10-20 LT LTEP08838897.0T patent/LT2211898T/lt unknown
- 2008-10-20 JP JP2010529300A patent/JP5509085B2/ja not_active Expired - Fee Related
- 2008-10-20 EA EA201070485A patent/EA020776B1/ru not_active IP Right Cessation
- 2008-10-20 MY MYPI2010001704A patent/MY159200A/en unknown
- 2008-10-20 AU AU2008314048A patent/AU2008314048B2/en not_active Ceased
- 2008-10-20 HU HUE08838897A patent/HUE032867T2/en unknown
-
2009
- 2009-03-27 CL CL2009000752A patent/CL2009000752A1/es unknown
-
2010
- 2010-04-12 ZA ZA2010/02548A patent/ZA201002548B/en unknown
- 2010-04-18 IL IL205175A patent/IL205175A0/en unknown
-
2014
- 2014-01-07 JP JP2014000825A patent/JP2014065739A/ja not_active Withdrawn
- 2014-02-14 US US14/181,153 patent/US20140314736A1/en not_active Abandoned
-
2017
- 2017-01-11 CY CY20171100041T patent/CY1118417T1/el unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060135425A1 (en) * | 2003-05-02 | 2006-06-22 | Paion Deutschland Gmbh | Intravenous injection of plasminogen non-neurotoxic activators for treating cerebral stroke |
Non-Patent Citations (2)
| Title |
|---|
| Amold et al., Intra-Arterial Thrombolysis in 100 Patients With Acute Stroke Due to Middle Cerebral Artery Occlusion, Stroke, July 2002, 33：1828-1833 * |
| MAULAZ A, PIECHOWSKI-JOWIAK B, MICHEL P, BOGOUSSLAVSKY J: "Selecting patients for early stroke treatment with penumbra images" CEREBROVASC DIS, ,2005, 20(suppl2)：19-24 * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Von Kummer et al. | Safety and efficacy of intravenous tissue plasminogen activator and heparin in acute middle cerebral artery stroke. | |
| Acampa et al. | Thrombolytic treatment of cardiac myxoma-induced ischemic stroke: a review | |
| Urbach et al. | Local intra-arterial fibrinolysis in thromboembolic “T” occlusions of the internal carotid artery | |
| Wu et al. | Assessing the clinical efficacy of recombinant tissue plasminogen activator on acute cerebral infarction | |
| EP2050462A1 (en) | Improved treatment of stroke patients | |
| TWI482628B (zh) | 新穎之血栓溶解病患次群 | |
| US20230139826A1 (en) | Combination treatment of stroke with plasmin-cleavable psd-95 inhibitor and reperfusion | |
| JP2022519327A (ja) | 頭蓋内出血の治療方法及び効果の評価方法 | |
| RU2323001C1 (ru) | Фармацевтическая композиция, обладающая фибринолитическим действием | |
| CA2966332A1 (en) | Methods and compositions for safe and effective thrombolysis | |
| EP2281569B1 (en) | Use of prourokinase in facilitated percutaneous coronary intervention in patients with acute myocardial infarction | |
| IL321911A (en) | Aptol molecules for the treatment of ischemic stroke and intracranial hemorrhages | |
| JP2011500617A5 (enExample) | ||
| HK1151233B (en) | Novel patient subgroups for thrombolysis | |
| Oguro et al. | Effect of one-shot intravenous 0.42 mega unit urokinase therapy in patients with acute ischemic stroke | |
| US20230285504A1 (en) | Inhibition of reperfusion injury with a psd-95 inhibitor | |
| Katsuhiko et al. | A Case of Atypical Capsular Warning Syndrome of Long Duration | |
| Petrov et al. | Iveta Tasheva, et al. Single Center Experience with Catheter Based Treatment in Acute Ischemic Stroke | |
| Csiba et al. | Fibrin-degrading drugs in acute stroke | |
| Rothwell | Surgical and Endovascular Interventions for the Secondary Prevention of Stroke | |
| Meschia et al. | Reopening occluded cerebral arteries | |
| Morihara et al. | Thrombolysis with Low dose Tissue Plasminogen Activator 3–4.5 Hours After Acute Ischemic Stroke in 5 Hospital Groups in Japan | |
| Csiba et al. | Fibrin-degrading drugs |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Annulment or lapse of patent due to non-payment of fees |